

CCCD Launches CLIA Compliant Diagnostic Testing Laboratory

September 04, 2009, Baltimore , MD. CCC Diagnostics (CCCD), has launched a CLIA compliant testing laboratory to market the DirectHit™ Panel for Breast Cancer as a diagnostic service. The DirectHit test panel analyzes an individual patient's tumor in order to indicate the sensitivity or resistance to FDA-approved, National Comprehensive Cancer Network (NCCN) recommended chemotherapy drugs.

The DirectHit Test Panel for Breast Cancer is the only predictive treatment outcome test service marketed for commonly prescribed anti-breast cancer chemotherapy drugs. The technology is based on the measurement of biomarker expression levels that are linked to chemotherapy response. The DirectHit test panel allows physicians to prescribe effective drug treatments, resulting in prolonged patient survival and significant financial savings.

CCCD, a Baltimore, MD based company, was formed in 2004 by a core group of former Johns Hopkins University researchers whose combined distinguished careers cover 90+ years of leadership in biophysics, oncology and imaging. The company's mission is to aid physicians in establishing a personalized treatment regime for individual cancer patients. CCCD is dedicated to "saving lives and life savings." CCCD is located at 3918 Vero Rd, Ste B, Baltimore, MD. The Company URL is www.ccediag.com, information on the test can be found at directhittest.com, and the telephone number is 410-633-4885.

DirectHit™ is a trademark of CCCD.